1. Age ≥18 years old2. Patients with previously untreated, locally advanced, inflammatory, or early-stage (tumor size exceeding 2 cm or lymph node-positive) HER2-positive breast cancer who do not have metastatic disease3. Pre-neoadjuvant therapy, tumor samples are available for examination.4. Physical status (PS) score of 1 or lower5. The baseline left ventricular ejection fraction (LVEF) was evaluated within 3 months preceding enrollment and was found to be greater than 55%. Here, ERBB2 is linked to breast cancer.